SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-101777
Filing Date
2024-04-19
Accepted
2024-04-19 08:31:56
Documents
14
Period of Report
2024-04-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d805983d8k.htm   iXBRL 8-K 25851
2 EX-10.1 d805983dex101.htm EX-10.1 5445
  Complete submission text file 0001193125-24-101777.txt   151983

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20240416.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20240416_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20240416_pre.xml EX-101.PRE 10810
18 EXTRACTED XBRL INSTANCE DOCUMENT d805983d8k_htm.xml XML 3551
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 24855692
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)